Predicting Prognosis of Mechanical Thrombectomy in Acute Ischemic Stroke Patients Using Modified DRAGON Score.
- Author:
Kun Hyun KIM
1
;
Myung Ho RHO
;
Yong Bum KIM
Author Information
- Publication Type:Original Article
- Keywords: Stroke; Endovascular procedures; Prognosis
- MeSH: Cerebral Arteries; Endovascular Procedures; Glucose; Humans; National Institutes of Health (U.S.); Prognosis*; ROC Curve; Stroke*; Thrombectomy*; Tissue Plasminogen Activator
- From:Journal of the Korean Neurological Association 2015;33(4):259-264
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: The DRAGON score is reportedly useful for predicting the outcome of intravenous thrombolysis. This study tested whether the modified DRAGON (mDRAGON) score, in which the onset-to-treatment time is extended, can predict the long-term outcome of transient ischemic stroke (AIS) patients who are candidates for mechanical thrombectomy (MT). METHODS: We assessed 40 AIS patients who were treated by MT alone or in combination with intravenous tissue plasminogen activator. The mDRAGON score is based on the following findings: hyperdense cerebral artery sign/early infarct signs on computed tomography (both=2, either=1, none=0), prestroke modified Rankin scale (mRS) score (>1=1), age (> or =80 years=2, 65-79 years=1, <65 years=0), glucose level (>144 mg/dL=1), onset-to-treatment time (>230 minutes=1), and baseline National Institutes of Health Stroke Scale score (>15=3, 10-15=2, 5-9=1, 0-4=0). Receiver operating characteristics (ROC) curve analysis was used to compare the performance of the mDRAGON score with the performances of other stroke prediction scores. RESULTS: Among 40 AIS patients treated with MT, the proportions with a good outcome (mRS score=0-2) in the groups with mDRAGON scores of 2 or 3, 4 or 5, 6 or 7, and 8-10 were 75%, 20%, 0%, and 0%, respectively, while the corresponding proportions with a poor outcome (mRS score=3-6) were 25%, 80%, 100%, and 100%. For the prediction of a good outcome at 3 months (mRS score=0-2), the area under the ROC curve of the mDRAGON scores was 0.87 (0.76-0.90). CONCLUSIONS: The mDRAGON score can be used to reliably predict the clinical outcome of AIS patients following endovascular treatment.
